Pfizer Pulls Plug On Two Unviable Indian Sites, Over 1,500 Jobs At Risk
Executive Summary
Pfizer is ending operations at two Indian manufacturing sites, including one with a checkered regulatory history. Approximately 1,700 jobs are at stake as a result of the action, though the US multinational clarified that it is not making a widespread exit from Indian manufacturing.
You may also be interested in...
Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?
Novartis India hands over sales and distribution of certain established brands, accounting for 50% of the 2020-2021 product revenues, to Dr Reddy’s as more foreign firms opt to leverage ground strengths of local players. Does it represent a wider trend where foreign firms are re-calibrating operations in India to focus energies on specialty and patented products?
Pfizer Must Correct Data Integrity Problems Seen At India Plant Globally, FDA Says
US FDA warning letter instructed Pfizer to implement a global corrective and preventive action plan to address widespread data integrity problems. While the impact of the warning letter on the site is expected to be minimal due to its closure, the global impact on the company’s sterile drug operations could be significant.
Pfizer plans to build sterile injectables site
Pfizer has announced plans to build “one of the most technically advanced sterile injectable pharmaceutical production facilities in the world”, strengthening the US firm’s capability to produce and supply “critical, life-saving injectable medicines” for patients globally.